- 1. Rediscovery of Cannabichromene (CBC)
- 2. Cannabichromene (CBC)
Rediscovery of cannabichromene (CBC)
Cannabis comprises over 460 chemicals of which over 60 are known as cannabinoids. Group 101 cannabinoids are responsible for most of the pharmaceutical effects of cannabis, of which CBC is one. Cannabichromene (CBC) is an abundant natural phytocannabinoid, yet it is unknown within the cannabis industry. It is however recognized by various studies, as an excellent anti-inflammatory and effective painkiller, but also having regenerative properties; data which now allows us to identify this “juvenile” phytocannabinoid with great therapeutic potential.
CBD is produced by enzymatic conversion of the cannabigerol precursor (CBG), just like THC and CBD. Cannabigerolic acid (CBGA decarboxylated to CBG) reacts with an enzyme in the glandular trichomes of the plant to form cannabichromenic acid (CBCA), and then in turn undergoes decarboxylation to become CBC. CBC shares the same molecular formula as THC and CBD. What binds it to the CB1 receptors, which is common to all phytocannabinoids, but we do not yet know how it exerts its effect on the cannabinoid receptors, we can just see its multiple therapeutic effects, and the fact that it does not is not psychotropic like THC. Several studies, even if preliminary, have shown that the potential of CBC is exerted on immunological (the immune system) and homeostatic (stability of neurotransmitter) processes.
A study on rats in 2010 demonstrates that CBC as well as CBD exert a convincing effect on symptoms related to depression. CBC leads to a reduction in immobility and this proportionally according to the dose administered (ie 40/50 mg / kg via the study on rats).
Using rodent models, researchers at the University of Mississippi found that rats treated with CBC performed significantly better on stress tests. Chronic stress is considered to be one of the primary triggers of depression.
Another 2010 study, still in animals, shows that CBC can reduce edema from swelling caused by lipopolysaccharide (a component of the bacterial wall, considered immunologically negative). The study determined that the synergistic activity of THC and CBC produced a strong anti-inflammatory effect.
Anti-nociceptive action (Analgesic)
Another study published in 2011 demonstrates that the combination of CBD and CBC reduces pain caused by nerve damage (nociceptive) in rats. A complex interaction between the proteins that control anti-nociceptive activity and the phytocannabinoids has been observed. Interestingly, these effects were blocked by CB1 receptor antagonists, indicating that CBC possesses affinities with such cannabinoid receptors, a synergy unique to it.
Researchers have demonstrated in 2012 that CBC could calm and normalize gastrointestinal hyper motility (diarrhea) in rats, and without reducing transit like diarrhea drugs (causing constipation). CBC shows promise for a cannabis-based treatment for inflammatory bowel disease.
The CBC would increase the viability of the cells, their vigor and their survival. This is what a 2013 study on mice… CBC acts on the metabolism and provides energy for cellular chemical reactions. Neurons are directly involved in the repair and homeostasis of cells in our body. CBC demonstrates once again, by its very nature, its great therapeutic potential, it could prove to be very promising in multiple applications.
Antifungal & antibacterial
Another study found that CBC had significant antibacterial properties. The cannabinoid is said to reduce the colonies of the dreaded E. coli and staphylococcus. CBC also has antifungal properties and may be as effective as vancomycin against MRSA.
Synergy against cancer
according to Halent Labs, a laboratory test center, the CBC is believed to inhibit inflammation and pain as well as stimulate bone growth and inhibit the growth of cancerous tumors. CBC has regenerative and anti-prolific effects through its interaction with anandamite, the natural endocannabinoid produced by the body. CBC inhibits the absorption of anandamide, which allows it to stay in the blood longer. Anandamide affects the CB1 and CB2 receptors, which has been found to fight against human breast cancer.
Not only does CBC have its own benefits, but it seems to work with all other cannabinoids (CBD, CBN, THC etc.) to produce a synergistic effect.
CBC Youthful Abundance
A study done in 1975, made on samples of Sativa Landrace (growing in their respective territories) reveals that cannabichromene is the second most abundant cannabinoid - It accounts for 64% of the total cannabinoid content! But the study takes place in the 70's, marijuana today is crossed to obtain high levels of THC, and for a decade of CBD… Which would indirectly reduce the rate of CBC…
Another study published this time in 2002, demonstrates that CBC dominates when the plant is juvenile, and its concentration decreases at maturity. CBC degrades naturally into canabicyclol when it is exposed to light or heat, just like THC which degrades to cannabinol (CBD)
Morphological variants of marijuana were discovered by the same 2002 study done on Sativa Landrace, The Inheritance of Chemical Phenotype in Cannabis sativa L. These are varieties with a 'prolonged juvenile chemotype'. Of configuration, the leaves that surround the flowers (the head), are much smaller, and produce less trichomes.
The study also establishes that these varieties (CJP) have a high level of CBC which is reduced according to the light but that these plants are a non-negligible raw material for a high purity pharmacopoeia - in terms of CBC.
Cannabichromene is a CB2 cannabinoid receptor agonist
A last 2018 study Cannabichromene (CBC) is one of the most abundant phytocannabinoids in Cannabis. It has modest anti-nociceptive and anti-inflammatory effects and potentiates certain effects of Δ9-tetrahydrocannabinol (THC) in vivo. CBC may contribute to the potential therapeutic efficacy of some cannabis preparations, potentially through modulation of inflammation by CB2.